Promontory Therapeutics
Johan Baeck currently serves as the Executive Vice President and Chief Medical Officer at Promontory Therapeutics, a position held since May 2022. Prior to this, Johan held multiple senior roles at Jounce Therapeutics, Inc., including Senior Vice President of Clinical Development and Medical Affairs, and Vice President of Clinical Development, Medical Affairs, and Biostatistics/Programming from March 2019 to April 2022. Johan also worked at Immunocore as VP & Head of Global Medical Affairs from May 2018 to March 2019. During a significant tenure at Novartis from 2009 to April 2018, Johan progressed from Senior Director of Clinical Development in Oncology to Executive Director of Global Medical Affairs and Medical Affairs Franchise Head for Oncology.
Promontory Therapeutics
Promontory Therapeutics Inc. is a clinical stage pharmaceutical company developing small molecule immunotherapies. The company's lead candidate, PT-112, is a novel chemical entity under clinical development that exhibits a unique combination of properties, including immunogenic cell death as well as osteotropism that confers advantages indealing with cancers that originate in or metastasize to the bone. Clinical data generated to date across three Phase 1 studies have demonstrated single-agent anti-cancer activity and an attractive tolerability profile, and three Phase 2 studies of PT-112 are underway. The company also sponsors the ongoing clinical study of PT-112 in combination with the PD-L1 inhibitor avelumab under a collaboration agreement with Pfizer and Merck KGaA, Darmstadt, Germany (operating as EMD Serono in the US and Canada), and has an active collaborative research and development agreement (CRADA) with the NCI to conduct a Phase 2 trial utilizing PT-112 in thymic epithelial tumors.